Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

MOVE vs DBVT vs ALKS vs MNMD

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MOVE
Movano Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$816M
5Y Perf.-98.4%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1669.52T
5Y Perf.-63.4%
ALKS
Alkermes plc

Biotechnology

NASDAQ • US
Market Cap$6.12B
5Y Perf.+94.1%
MNMD
Mind Medicine (MindMed) Inc.

Biotechnology

HealthcareNASDAQ • CA
Market Cap$2.04B
5Y Perf.-54.8%

MOVE vs DBVT vs ALKS vs MNMD — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MOVE logoMOVE
DBVT logoDBVT
ALKS logoALKS
MNMD logoMNMD
IndustryMedical - DevicesBiotechnologyBiotechnologyBiotechnology
Market Cap$816M$1669.52T$6.12B$2.04B
Revenue (TTM)$500K$0.00$1.48B$0.00
Net Income (TTM)$-17M$-168M$242M$-184M
Gross Margin-270.2%86.3%
Operating Margin-31.6%17.2%
Forward P/E25.3x
Total Debt$186K$22M$70M$0.00
Cash & Equiv.$8M$194M$1.12B$258M

MOVE vs DBVT vs ALKS vs MNMDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MOVE
DBVT
ALKS
MNMD
StockMar 21May 26Return
Movano Inc. (MOVE)1001.6-98.4%
DBV Technologies S.… (DBVT)10036.6-63.4%
Alkermes plc (ALKS)100194.1+94.1%
Mind Medicine (Mind… (MNMD)10045.2-54.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: MOVE vs DBVT vs ALKS vs MNMD

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Mind Medicine (MindMed) Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
MOVE
Movano Inc.
The Specific-Use Pick

MOVE plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
Best for: income & stability
ALKS
Alkermes plc
The Growth Play

ALKS carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.

  • Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.06, current ratio 3.55x
  • -5.2% revenue growth vs DBVT's -100.0%
Best for: growth exposure and sleep-well-at-night
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder

MNMD is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 5.1% 10Y total return vs ALKS's -4.6%
  • +215.9% vs ALKS's +15.4%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthALKS logoALKS-5.2% revenue growth vs DBVT's -100.0%
Quality / MarginsALKS logoALKS16.4% margin vs MOVE's -34.1%
Stability / SafetyALKS logoALKSBeta 1.06 vs MOVE's 1.98
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)MNMD logoMNMD+215.9% vs ALKS's +15.4%
Efficiency (ROA)ALKS logoALKS10.5% ROA vs MOVE's -306.8%

MOVE vs DBVT vs ALKS vs MNMD — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MOVEMovano Inc.

Segment breakdown not available.

DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
MNMDMind Medicine (MindMed) Inc.

Segment breakdown not available.

MOVE vs DBVT vs ALKS vs MNMD — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 4 of 6 comparable metrics.

ALKS and MNMD operate at a comparable scale, with $1.5B and $0 in trailing revenue. ALKS is the more profitable business, keeping 16.4% of every revenue dollar as net income compared to MOVE's -34.1%. On growth, MOVE holds the edge at +60.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricMOVE logoMOVEMovano Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcMNMD logoMNMDMind Medicine (Mi…
RevenueTrailing 12 months$500,000$0$1.5B$0
EBITDAEarnings before interest/tax-$16M-$112M$281M-$156M
Net IncomeAfter-tax profit-$17M-$168M$242M-$184M
Free Cash FlowCash after capex-$14M-$151M$480M-$161M
Gross MarginGross profit ÷ Revenue-2.7%+86.3%
Operating MarginEBIT ÷ Revenue-31.6%+17.2%
Net MarginNet income ÷ Revenue-34.1%+16.4%
FCF MarginFCF ÷ Revenue-27.1%+32.5%
Rev. Growth (YoY)Latest quarter vs prior year+60.0%-10.6%
EPS Growth (YoY)Latest quarter vs prior year+53.0%+91.5%-67.0%-22.0%
ALKS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — MOVE and DBVT and ALKS each lead in 1 of 3 comparable metrics.
MetricMOVE logoMOVEMovano Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcMNMD logoMNMDMind Medicine (Mi…
Market CapShares × price$816M$1669.52T$6.1B$2.0B
Enterprise ValueMkt cap + debt − cash$808M$1669.52T$5.1B$1.8B
Trailing P/EPrice ÷ TTM EPS-34.72x-0.74x25.35x-10.04x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple18.02x
Price / SalesMarket cap ÷ Revenue805.09x4.14x
Price / BookPrice ÷ Book value/share110.89x0.64x3.36x5.56x
Price / FCFMarket cap ÷ FCF12.73x
Evenly matched — MOVE and DBVT and ALKS each lead in 1 of 3 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 7 of 9 comparable metrics.

ALKS delivers a 14.5% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-4 for MOVE. MOVE carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs MNMD's 3/9, reflecting strong financial health.

MetricMOVE logoMOVEMovano Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcMNMD logoMNMDMind Medicine (Mi…
ROE (TTM)Return on equity-4.4%-130.2%+14.5%-55.3%
ROA (TTM)Return on assets-3.1%-89.0%+10.5%-41.8%
ROICReturn on invested capital+18.9%-3.9%
ROCEReturn on capital employed-4.3%-145.7%+14.2%-52.2%
Piotroski ScoreFundamental quality 0–96473
Debt / EquityFinancial leverage0.03x0.13x0.04x
Net DebtTotal debt minus cash-$8M-$172M-$1.0B-$258M
Cash & Equiv.Liquid assets$8M$194M$1.1B$258M
Total DebtShort + long-term debt$186,000$22M$70M$0
Interest CoverageEBIT ÷ Interest expense-10.38x-189.82x24.74x-14.63x
ALKS leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MNMD leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,440 today (with dividends reinvested), compared to $168 for MOVE. Over the past 12 months, MNMD leads with a +215.9% total return vs ALKS's +15.4%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.4% vs MOVE's -56.4% — a key indicator of consistent wealth creation.

MetricMOVE logoMOVEMovano Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcMNMD logoMNMDMind Medicine (Mi…
YTD ReturnYear-to-date+54.2%+2.3%+28.3%+51.7%
1-Year ReturnPast 12 months+52.1%+110.7%+15.4%+215.9%
3-Year ReturnCumulative with dividends-91.7%+18.1%+23.1%+506.7%
5-Year ReturnCumulative with dividends-98.3%-69.6%+64.4%-58.8%
10-Year ReturnCumulative with dividends-98.6%-87.1%-4.6%+512.1%
CAGR (3Y)Annualised 3-year return-56.4%+5.7%+7.2%+82.4%
MNMD leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than MOVE's 1.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 99.2% from its 52-week high vs MOVE's 38.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMOVE logoMOVEMovano Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcMNMD logoMNMDMind Medicine (Mi…
Beta (5Y)Sensitivity to S&P 5001.98x1.26x1.06x1.68x
52-Week HighHighest price in past year$34.87$26.18$36.55$21.09
52-Week LowLowest price in past year$4.67$7.53$25.17$6.03
% of 52W HighCurrent price vs 52-week peak+38.8%+74.4%+99.2%+98.1%
RSI (14)Momentum oscillator 0–10042.643.757.164.9
Avg Volume (50D)Average daily shares traded70K249K2.3M803K
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: MOVE as "Buy", DBVT as "Buy", ALKS as "Buy", MNMD as "Buy". Consensus price targets imply 137.7% upside for DBVT (target: $46) vs -3.3% for MNMD (target: $20).

MetricMOVE logoMOVEMovano Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcMNMD logoMNMDMind Medicine (Mi…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$46.33$44.00$20.00
# AnalystsCovering analysts415281
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MNMD leads in 1 (Total Returns). 1 tied.

Best OverallAlkermes plc (ALKS)Leads 3 of 6 categories
Loading custom metrics...

MOVE vs DBVT vs ALKS vs MNMD: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is MOVE or DBVT or ALKS or MNMD a better buy right now?

Alkermes plc (ALKS) offers the better valuation at 25.

3x trailing P/E, making it the more compelling value choice. Analysts rate Movano Inc. (MOVE) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — MOVE or DBVT or ALKS or MNMD?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +64.

4%, compared to -98. 3% for Movano Inc. (MOVE). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus MOVE's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — MOVE or DBVT or ALKS or MNMD?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus Movano Inc. 's 1. 98β — meaning MOVE is approximately 86% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Movano Inc. (MOVE) carries a lower debt/equity ratio of 3% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

04

Which is growing faster — MOVE or DBVT or ALKS or MNMD?

On earnings-per-share growth, the picture is similar: Movano Inc.

grew EPS 38. 1% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — MOVE or DBVT or ALKS or MNMD?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -23. 4% for Movano Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -23. 9% for MOVE. At the gross margin level — before operating expenses — ALKS leads at 86. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — MOVE or DBVT or ALKS or MNMD?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is MOVE or DBVT or ALKS or MNMD better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

06)). Movano Inc. (MOVE) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -4. 6%, MOVE: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between MOVE and DBVT and ALKS and MNMD?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

MOVE

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 30%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

Quality Business

  • Market Cap > $100B
  • Net Margin > 9%
Run This Screen
Stocks Like

MNMD

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.